Protease inhibitors: changing the way AIDS case management does business.
The purpose of the qualitative evaluation study discussed in this article was to examine the AIDS case management model under which five nonprofit AIDS service organizations (ASOs) in Midcity were operating. The study was organized around 40 qualitative interviews with executive directors, directors, and case managers. The finding was that AIDS case management is evolving to accommodate the changing environmental/contextual conditions that have resulted from combination drug therapies (protease inhibitors) introduced in 1996. The agencies are responding to the changes individually rather than as a network, and responses vary among the agencies. Institutional theory, an examination of the interconnectedness of clients, the ASOs, and their environmental context guided the analysis of the findings.
Merithew
M A
MA
Davis-Satterla
L
L
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019090:Case Management / Q000191:economics / Q000639:trends*; D005378:Financial Support; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D017146:Models, Organizational; D009936:Organizational Innovation; D010349:Patient Compliance; D014481:United States
D017320:HIV Protease Inhibitors